Analyst firms · HSBC · ABBV
HSBC ABBV price target and rating history
AbbVie Inc. (ABBV) · Health Care
HSBC rates AbbVie Inc. (ABBV) Buy with a $265 price target, as of its latest action on Dec 10, 2025. It has published 5 rating actions on ABBV since July 2023, including 2 upgrades and 2 downgrades. Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. HSBC's $265 is 1% above that.
- Current rating
- Buy
- Price target
- $265
- Median target, all firms
- $263.50
- Actions on ABBV
- 5
HSBC price target on ABBV
Every HSBC rating on ABBV
- Dec 10, 2025
- Oct 1, 2025DowngradeHSBC downgrades to Hold from Buy
- Jun 5, 2024
- Dec 18, 2023DowngradeHSBC downgrades to Hold from Buy
- Jul 14, 2023
How other firms rate ABBV
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Erste Group | Buy | Aug 5, 2026 | |
| BofA Securities | Buy | $234 | Apr 30, 2026 |
| Canaccord Genuity | Buy | $262 | Apr 21, 2026 |
| RBC Capital Markets | Outperform | $260 | Feb 25, 2026 |
| Barclays | Overweight | $275 | Feb 20, 2026 |
| UBS | Neutral | $240 | Jan 7, 2026 |
| HSBC | Buy | $265 | Dec 10, 2025 |
| Scotiabank | Sector Outperform | $280 | Nov 13, 2025 |
Questions about HSBC and ABBV
- What is HSBC's price target for ABBV?
- HSBC's latest stated price target for AbbVie Inc. (ABBV) is $265, from its action on Dec 10, 2025.
- What is HSBC's rating on ABBV?
- HSBC rates ABBV Buy, a bullish rating, as of Dec 10, 2025.
- When did HSBC last change its view on ABBV?
- On Dec 10, 2025, HSBC upgrades to Buy from Hold, price target $265.
- How does HSBC's ABBV target compare with other analysts?
- Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. HSBC's $265 is 1% above that.
More ABBV rating histories
All HSBC ratingsABBV news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.